MAO-B inhibition by a single dose of 1-deprenyl or lazabemide does not prevent neuronal damage following focal cerebral ischaemia in rats

Pharmacology and Toxicology

Volumn 87, Issue 5, 2000, Pages 242-245

  Jolkkonen, Jukka ^a   Kauppinen, Risto ^a   Nyman, Leena ^b   Haapalinna, Antti ^b   Sivenius, Juhani ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b ORION CORPORATION   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

LAZABEMIDE; MONOAMINE OXIDASE B INHIBITOR; MONOAMINE OXIDASE INHIBITOR; SELEGILINE;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN ISCHEMIA; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG EFFICACY; MIDDLE CEREBRAL ARTERY OCCLUSION; NERVE CELL LESION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; REPERFUSION;

ANIMALIA; GYMNOMYZA SAMOENSIS;

EID: 0033710556     PISSN: 09019928     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0773.2000.d01-81.x     Document Type: Article

References (21)

1. Ansari, K. S., P. H. Yu, T. P. A. Kruck & W. G. Tatton: Rescue of axotomized immature rat facial motoneurons by R(-)-(-)deprenyl: Stereospecificity and independence from monoamine oxidase inhibition. J. Neurosci. 1993, 13, 4042-4053.
2. Biagini, G., A. Frasoldati, K. Fuxe & L. Agnati: The concept of astrocyte-kinetic drug in the treatment of neurodegenerative diseases: Evidence for (-)deprenyl-induced activation of reactive astrocytes. Neurochem. Int. 1994, 25, 17-22.
3. Borbe, H. O., G. Niebch & B. Nickel: Kinetic evaluation of MAO-B-activity following oral administration of selegeline and desmethyl-selegeline in the rat. J. Neural. Transm. 1990, 32, 131-137.
4. Globus, M. Y., R. Busto, W. D. Dietrich, E. Martinez & M. D. Ginsberg: Intra-ischemic extracellular release of dopamine and glutamate is associated with striatal vulnerability to ischemia. Neurosci. Lett. 1988, 91, 36-40.
5. Holschneider, D. P., O. U. Schremin, L. Huynh, K. Chen & J. C. Shih: Lack of protection from ischemic injury of monoamine oxidase B-deficient mice following middle cerebral artery occlusion. Neurosci. Lett. 1999, 259, 161-164.
6. Keller, H. H., R. Kettler & M. Da Prada: Short-acting novel MAO inhibitors: In vitro evidence for the reversibility of MAO inhibition by moclobemide and Ro 16-6491. Naunyn-Schmiedeberg's Arch. Pharmacol. 1987, 335, 12-20.
7. Knoll, J: (-)Deprenyl (selegiline), a catecholaminergic activity enhancer (CAE) substance acting in the brain. Pharmacology & Toxicology 1998, 82, 57-66.
8. Knollema, S., W. Aukema, H. Hom, J. Korf & G. J. T. Horst: L-(-)deprenyl reduces brain damage in rats exposed to transient hypoxia-ischemia. Stroke 1995, 26, 1883-1887.
9. Koulu, M., M. Scheinin, A. Kaarttinen, J. Kallio & K. Pyykkö: Inhibition of monoamine oxidase by moclobemide: Effects on monoamine metabolism and secretion of anterior pituitary hormones and cortisol in healthy volunteer. Brit J. Clin. Pharmacol. 1989, 27, 243-255.
10. Lahtinen, H., J. Koistinaho, R. Kauppinen, A. Haapalinna, R. Keinänen & J. Sivenius: Selegeline treatment after transient global ischemia in gerbils enhances the survival of CA1 pyramidal cells in the hippocampus. Brain Res. 1997, 757, 260-267.
11. +)-induced apoptosis independent of MAO-B inhibition. Neurosci. Lett. 1997, 224, 197-200.
12. Longa, Z. E., P. R. Weinstein, S. Carlson & R. Cummins: Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke 1989, 20, 84-91.
13. Matsui, Y. & Y. Kumagae: Monoamine oxidase inhibitors prevent striatal neuronal necrosis induced by transient forebrain ischemia. Neurosci. Lett. 1991, 126, 175-178.
14. Mytilineou, C., P. M. Radcliffe & C. W. Olanow: L-(-)-Desmethylselegeline, a metabolite of selegeline L-(-)-deprenyl), protects mesencephalic dopamine neurons from excitotoxicity in vitro. J. Neurochem. 1997, 68, 434-436.
15. Salo, P. T. & W. G. Tatton: (-)Deprenyl reduces the death of motoneurons caused by axotomy. J. Neurosci. Res. 1992, 31, 394-400.
16. Semkova, I., P. Wolz, M. Schilling & J. Krieglstein: (-)Deprenyl enhances NGF synthesis and protects central nervous system neurons from excitotoxic and ischemic damage. Eur. J. Pharmacol. 1996, 315, 19-30.
17. Simonson, S. G., J. Zhang, A. T. Canada, Y.-F. Su, H. Benveniste & C. A. Piantadosi: Hydrogen peroxide production by monoamine oxidase during ischemia-reperfusion in the rat brain. J. Cereb. Blood Flow Metab. 1993, 13, 125-134.
18. Suzuki, T., N. Akaike, K.-I. Ueno, Y. Tanaka & N. Himori: MAO inhibitors, clorgyline and lazabemide, prevent hydroxyl radical generation caused by brain ischemia/reperfusion in mice. Pharmacology 1995, 50, 357-362.
19. Swanson, R. A., M. T. Morton, G. Tsao-Wu, R. A. Savalos, C. Davidson & F. R. Sharp: A semiautomated method for measuring brain infarct volume. J. Cereb. Blood Flow Metab. 1990, 10, 290-293.
20. Thomas, C. E., E. W. Huber & D. F. Ohlweiler: Hydroxyl and peroxyl radical trapping by the monoamine oxidase-B inhibitors deprenyl and MDL 72,974A: Implications for protection of biological substrates. Free Rad. Biol. Med. 1997, 22, 733-737.
21. + in vivo. Eur. J. Pharmacol. 1993, 243, 241-247.